vs
加拿大帝国商业银行（CM）与梯瓦制药（TEVA）财务数据对比。点击上方公司名可切换其他公司
加拿大帝国商业银行的季度营收约是梯瓦制药的1.3倍（$6.1B vs $4.7B），加拿大帝国商业银行净利率更高（36.9% vs 10.2%，领先26.7%）
加拿大帝国商业银行是加拿大历史悠久的主流商业银行，其前身之一加拿大帝国银行于1873年开始运营，1961年与加拿大商业银行合并后正式成立，是加拿大五大银行之一，服务覆盖加拿大本土及全球多个地区。
梯瓦制药工业有限公司是以色列跨国制药企业，核心业务聚焦仿制药研发生产，同时布局品牌药、药用活性成分（API）业务，也小范围开展合同生产服务及对外授权合作相关业务。
CM vs TEVA — 直观对比
营收规模更大
CM
是对方的1.3倍
$4.7B
净利率更高
CM
高出26.7%
10.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $6.1B | $4.7B |
| 净利润 | $2.3B | $481.0M |
| 毛利率 | — | 56.4% |
| 营业利润率 | — | 6.4% |
| 净利率 | 36.9% | 10.2% |
| 营收同比 | — | 11.4% |
| 净利润同比 | — | 321.7% |
| 每股收益（稀释后） | — | $0.42 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CMTEVA
| Q1 26 | $6.1B | — | ||
| Q4 25 | — | $4.7B | ||
| Q3 25 | $5.3B | $4.5B | ||
| Q2 25 | $5.1B | $4.2B | ||
| Q1 25 | — | $3.9B | ||
| Q4 24 | — | $4.2B | ||
| Q3 24 | — | $4.3B | ||
| Q2 24 | — | $4.2B |
净利润CMTEVA
| Q1 26 | $2.3B | — | ||
| Q4 25 | — | $481.0M | ||
| Q3 25 | $1.5B | $433.0M | ||
| Q2 25 | $1.5B | $282.0M | ||
| Q1 25 | — | $214.0M | ||
| Q4 24 | — | $-217.0M | ||
| Q3 24 | — | $-437.0M | ||
| Q2 24 | — | $-846.0M |
毛利率CMTEVA
| Q1 26 | — | — | ||
| Q4 25 | — | 56.4% | ||
| Q3 25 | — | 51.4% | ||
| Q2 25 | — | 50.3% | ||
| Q1 25 | — | 48.2% | ||
| Q4 24 | — | 50.2% | ||
| Q3 24 | — | 49.6% | ||
| Q2 24 | — | 48.6% |
营业利润率CMTEVA
| Q1 26 | — | — | ||
| Q4 25 | — | 6.4% | ||
| Q3 25 | — | 19.7% | ||
| Q2 25 | — | 10.9% | ||
| Q1 25 | — | 13.3% | ||
| Q4 24 | — | -0.7% | ||
| Q3 24 | — | -1.2% | ||
| Q2 24 | — | -0.1% |
净利率CMTEVA
| Q1 26 | 36.9% | — | ||
| Q4 25 | — | 10.2% | ||
| Q3 25 | 28.9% | 9.7% | ||
| Q2 25 | 28.6% | 6.8% | ||
| Q1 25 | — | 5.5% | ||
| Q4 24 | — | -5.1% | ||
| Q3 24 | — | -10.1% | ||
| Q2 24 | — | -20.3% |
每股收益（稀释后）CMTEVA
| Q1 26 | — | — | ||
| Q4 25 | — | $0.42 | ||
| Q3 25 | — | $0.37 | ||
| Q2 25 | — | $0.24 | ||
| Q1 25 | — | $0.18 | ||
| Q4 24 | — | $-0.19 | ||
| Q3 24 | — | $-0.39 | ||
| Q2 24 | — | $-0.75 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.0B | $3.6B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $47.9B | $7.9B |
| 总资产 | $826.8B | $40.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CMTEVA
| Q1 26 | $8.0B | — | ||
| Q4 25 | — | $3.6B | ||
| Q3 25 | $13.9B | $2.2B | ||
| Q2 25 | $10.2B | $2.2B | ||
| Q1 25 | — | $1.7B | ||
| Q4 24 | — | $3.3B | ||
| Q3 24 | — | $3.3B | ||
| Q2 24 | — | $2.3B |
股东权益CMTEVA
| Q1 26 | $47.9B | — | ||
| Q4 25 | — | $7.9B | ||
| Q3 25 | $45.9B | $7.3B | ||
| Q2 25 | $45.2B | $6.8B | ||
| Q1 25 | — | $6.3B | ||
| Q4 24 | — | $5.4B | ||
| Q3 24 | — | $6.1B | ||
| Q2 24 | — | $6.4B |
总资产CMTEVA
| Q1 26 | $826.8B | — | ||
| Q4 25 | — | $40.7B | ||
| Q3 25 | $804.6B | $39.9B | ||
| Q2 25 | $795.8B | $40.1B | ||
| Q1 25 | — | $38.4B | ||
| Q4 24 | — | $39.3B | ||
| Q3 24 | — | $41.8B | ||
| Q2 24 | — | $41.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.6B | $1.2B |
| 自由现金流经营现金流 - 资本支出 | — | $1.0B |
| 自由现金流率自由现金流/营收 | — | 21.6% |
| 资本支出强度资本支出/营收 | — | 3.0% |
| 现金转化率经营现金流/净利润 | -0.69× | 2.41× |
| 过去12个月自由现金流最近4个季度 | — | $1.1B |
8季度趋势，按日历期对齐
经营现金流CMTEVA
| Q1 26 | $-1.6B | — | ||
| Q4 25 | — | $1.2B | ||
| Q3 25 | $4.3B | $369.0M | ||
| Q2 25 | $667.2M | $227.0M | ||
| Q1 25 | — | $-105.0M | ||
| Q4 24 | — | $575.0M | ||
| Q3 24 | — | $693.0M | ||
| Q2 24 | — | $103.0M |
自由现金流CMTEVA
| Q1 26 | — | — | ||
| Q4 25 | — | $1.0B | ||
| Q3 25 | — | $233.0M | ||
| Q2 25 | — | $131.0M | ||
| Q1 25 | — | $-232.0M | ||
| Q4 24 | — | $446.0M | ||
| Q3 24 | — | $545.0M | ||
| Q2 24 | — | $6.0M |
自由现金流率CMTEVA
| Q1 26 | — | — | ||
| Q4 25 | — | 21.6% | ||
| Q3 25 | — | 5.2% | ||
| Q2 25 | — | 3.1% | ||
| Q1 25 | — | -6.0% | ||
| Q4 24 | — | 10.5% | ||
| Q3 24 | — | 12.6% | ||
| Q2 24 | — | 0.1% |
资本支出强度CMTEVA
| Q1 26 | — | — | ||
| Q4 25 | — | 3.0% | ||
| Q3 25 | — | 3.0% | ||
| Q2 25 | — | 2.3% | ||
| Q1 25 | — | 3.3% | ||
| Q4 24 | — | 3.1% | ||
| Q3 24 | — | 3.4% | ||
| Q2 24 | — | 2.3% |
现金转化率CMTEVA
| Q1 26 | -0.69× | — | ||
| Q4 25 | — | 2.41× | ||
| Q3 25 | 2.80× | 0.85× | ||
| Q2 25 | 0.46× | 0.80× | ||
| Q1 25 | — | -0.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CM
暂无分部数据
TEVA
| Other | $2.0B | 42% |
| Generics Medicians Including Otc And Biosimilars | $672.0M | 14% |
| Other Products | $608.0M | 13% |
| License | $529.0M | 11% |
| Distribution Service | $366.0M | 8% |
| Other Activities | $227.0M | 5% |
| Ajovy | $106.0M | 2% |
| COPAXONE | $77.0M | 2% |
| Respiratory Product | $65.0M | 1% |
| Uzedy | $55.0M | 1% |
| Bendeka And Treanda | $36.0M | 1% |
